Already a month into 2023 but still a lot of big events coming this quarter. We have a number of readouts coming including GTHX phase 3 data in Feb, ASCO-GU meeting mid Feb, and lots of NASH/Liver readouts throughout the year. The table below highlights catalysts coming in the next few weeks to keep an eye on. Connect with us and fellow traders in our Discord chat.
BPIQ Weekly Catalyst Watchlist Table:
Weekly Watchlist Highlights:
REGN has a PDUFA date February 11, 2023 for their drug EYLEA (aflibercept) for retinopathy of prematurity (ROP) in preterm infants.
TVTX's asset Sparsentan has a PDUFA target action date of February 17, 2023 for the possible treatment of IgA Nephropathy. Sparsentan is a dual endothelin angiotensin receptor antagonist (DEARA). Read more in our TVTX PDUFA post.
CYTK's asset Omecamtiv Mecarbil has a PDUFA target action date of February 28, 2023 for the possible treatment of heart failure with reduced ejection fraction (HErEF). Omecamtiv Mecarbil is a selective cardiac myosin activator. Read more in our CYTK PDUFA post.
Want access to all the biotech data and even monthly stock ideas? Get 40% Off Premium!
Comments